NASDAQ:JAZZ
Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc's revenue grew 4.9% in fiscal 2025 to $4.3B while operating margin fell to −10.1%, its lowest in 10 years. Free cash flow was $1.3B, 30.4% of revenue, and the diluted share count fell 7.6%.Summary generated from Jazz Pharmaceuticals plc's SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$4.3B
Revenue growth+4.9%
Revenue, 5-yr CAGR+12.5%
Gross marginn/a
Operating margin−10.1%
Net margin−8.3%
ROIC−4.2%
Return on equity−8.5%
Debt / equity1.24
Free cash flow$1.3B
FCF margin30.4%
Share count change−7.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3,094 | 3,659 | 3,834 | 4,069 | 4,268 |
| Operating income | 170 | −66 | 579 | 717 | −430 |
| Net income | −330 | −224 | 415 | 560 | −356 |
| Free cash flow | 751 | 1,243 | 1,068 | 1,358 | 1,297 |
Recent filings
- 8-KDirector or officer change
Oct 9, 2026 - 4Insider transaction report
Oct 7, 2026 - 4Insider transaction report
Oct 5, 2026 - 8-KEntry into a material agreement
Sep 23, 2026 - 8-KRegulation FD disclosure
Sep 15, 2026 - 8-KEntry into a material agreement
Aug 31, 2026 - 8-KOther events
Aug 25, 2026 - 8-KEntry into a material agreement
Aug 10, 2026